-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Corbus Pharmaceuticals, Lowers Price Target to $30

Benzinga·05/27/2026 13:32:29
Listen to the news
Wedbush analyst Robert Driscoll maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and lowers the price target from $38 to $30.